Literature DB >> 17467808

Genetic variability at HPA axis in major depression and clinical response to antidepressant treatment.

Sergi Papiol1, Bárbara Arias, Cristóbal Gastó, Blanca Gutiérrez, Rosa Catalán, Lourdes Fañanás.   

Abstract

BACKGROUND: Dysregulation of the hypothalamic-pituitary-adrenal (HPA) axis has been observed in major depression. Normalization of HPA axis has been suggested to play a role in the mechanisms of action of antidepressants. Our aim was to investigate the influence of genetic variants in CRHR1, CRHR2, CRH-BP and FKBP5 genes on both the vulnerability for depression and the response to antidepressant treatment.
METHODS: The sample consisted of 159 depressive outpatients and 96 healthy controls of Spanish origin. Patients were assessed for clinical features including, among others, age of onset, seasonality or suicidal behavior. The episode was treated with citalopram and followed along 12 weeks. Severity of symptoms was evaluated at the inclusion and then monthly along the follow-up using a 21-item Hamilton Depression Rating Score (HDRS). SNPs were assayed using Applied Biosystems SNaP-Shot and TaqMan technology.
RESULTS: rs110402, in CRHR1 gene, was associated with an increased risk to present a seasonal pattern and an early age of onset of the first depressive episode. Allele G carriers of rs2270007 of CRHR2 gene, showed a worse overall response to citalopram along time of follow-up (Genotype effect F=7.45, P=0.007). G allele carriers showed 2.93 increased risk (95% CI [1.24-6.90]) for non-responding at 4th week to citalopram treatment (chi(2)=7.59, df=1, P=0.006). LIMITATIONS: On the light of the moderate sample size, associations based on the mentioned polymorphisms need to be considered with caution and require further replication studies in other samples.
CONCLUSIONS: Variability at genes encoding proteins with a pivotal role in HPA axis regulation seems to influence i) the expression of severity variables of the depressive spectrum including early age of onset or a seasonal pattern and ii) the interindividual variation in clinical response to SSRI antidepressants.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17467808     DOI: 10.1016/j.jad.2007.02.017

Source DB:  PubMed          Journal:  J Affect Disord        ISSN: 0165-0327            Impact factor:   4.839


  55 in total

Review 1.  Gene-environment interaction in major depression and antidepressant treatment response.

Authors:  Robert Keers; Rudolf Uher
Journal:  Curr Psychiatry Rep       Date:  2012-04       Impact factor: 5.285

Review 2.  Pharmacogenetics of antidepressant response.

Authors:  Stefano Porcelli; Antonio Drago; Chiara Fabbri; Sara Gibiino; Raffaella Calati; Alessandro Serretti
Journal:  J Psychiatry Neurosci       Date:  2011-03       Impact factor: 6.186

Review 3.  Evidence for the role of corticotropin-releasing factor in major depressive disorder.

Authors:  R Parrish Waters; Marion Rivalan; D A Bangasser; J M Deussing; M Ising; S K Wood; F Holsboer; Cliff H Summers
Journal:  Neurosci Biobehav Rev       Date:  2015-08-10       Impact factor: 8.989

Review 4.  Neuropeptide receptor ligands as drugs for psychiatric diseases: the end of the beginning?

Authors:  Guy Griebel; Florian Holsboer
Journal:  Nat Rev Drug Discov       Date:  2012-05-18       Impact factor: 84.694

Review 5.  Pharmacogenetics of major depression: insights from level 1 of the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial.

Authors:  Magnus Lekman; Silvia Paddock; Francis J McMahon
Journal:  Mol Diagn Ther       Date:  2008       Impact factor: 4.074

6.  Corticotropin releasing hormone receptor 2 (CRHR-2) gene is associated with decreased risk and severity of posttraumatic stress disorder in women.

Authors:  Erika J Wolf; Karen S Mitchell; Mark W Logue; Clinton T Baldwin; Annemarie F Reardon; Donald E Humphries; Mark W Miller
Journal:  Depress Anxiety       Date:  2013-10-09       Impact factor: 6.505

Review 7.  The promise and reality of pharmacogenetics in psychiatry.

Authors:  Peter P Zandi; Jennifer T Judy
Journal:  Psychiatr Clin North Am       Date:  2010-03

8.  Association of the calcyon neuron-specific vesicular protein gene (CALY) with adolescent smoking initiation in China and California.

Authors:  Dalin Li; Stephanie J London; Jinghua Liu; Wonho Lee; Xuejuan Jiang; David Van Den Berg; Andrew W Bergen; Denise Nishita; Nahid Waleh; Gary E Swan; Peggy Gallaher; Chih-Ping Chou; Jean C Shih; Jennifer B Unger; W James Gauderman; Frank Gilliland; C Anderson Johnson; David V Conti
Journal:  Am J Epidemiol       Date:  2011-03-16       Impact factor: 4.897

9.  Association of FKBP5 polymorphisms with suicidal events in the Treatment of Resistant Depression in Adolescents (TORDIA) study.

Authors:  David Brent; Nadine Melhem; Robert Ferrell; Graham Emslie; Karen Dineen Wagner; Neal Ryan; Benedetto Vitiello; Boris Birmaher; Taryn Mayes; Jamie Zelazny; Matthew Onorato; Bernie Devlin; Greg Clarke; Lynn DeBar; Marty Keller
Journal:  Am J Psychiatry       Date:  2009-12-15       Impact factor: 18.112

Review 10.  The CRF system, stress, depression and anxiety-insights from human genetic studies.

Authors:  E B Binder; C B Nemeroff
Journal:  Mol Psychiatry       Date:  2009-12-15       Impact factor: 15.992

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.